NYSE:AZN - AstraZeneca Stock Price, Price Target & More

Get Started

$37.04 +0.16 (+0.43 %)

(As of 05/27/2018 04:00 PM ET)

Previous Close$37.04

Today's Range$36.74 - $37.15

52-Week Range$28.43 - $37.30

Volume5.45 million shs

Average Volume4.64 million shs

Market Capitalization$93.82 billion

P/E Ratio8.65

Dividend Yield3.70%

Beta0.61

About AstraZeneca (NYSE:AZN)

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. AstraZeneca PLC serves primary care and specialty care physicians through distributors and local representative offices. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNYSE:AZN

CUSIPN/A

Webwww.astrazeneca.com

Phone44-20-3749-5000

Debt

Debt-to-Equity Ratio1.08

Current Ratio0.73

Quick Ratio0.62

Price-To-Earnings

Trailing P/E Ratio8.65

Forward P/E Ratio21.79

P/E Growth1.95

Sales & Book Value

Annual Sales$22.47 billion

Price / Sales4.18

Cash Flow$3.3399 per share

Price / Cash11.09

Book Value$5.75 per share

Price / Book6.44

Profitability

EPS (Most Recent Fiscal Year)$4.28

Net Income$3.00 billion

Net Margins12.61%

Return on Equity30.73%

Return on Assets7.44%

Miscellaneous

Employees59,700

Outstanding Shares2,532,900,000

AstraZeneca (NYSE:AZN) Frequently Asked Questions

What is AstraZeneca's stock symbol?

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca announced a semiannual dividend on Monday, February 5th. Investors of record on Friday, February 16th will be paid a dividend of $0.95 per share on Monday, March 19th. This represents a dividend yield of 5.62%. The ex-dividend date is Thursday, February 15th. View AstraZeneca's Dividend History.

When did AstraZeneca's stock split? How did AstraZeneca's stock split work?

Shares of AstraZeneca split on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly issued shares were distributed to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

How were AstraZeneca's earnings last quarter?

AstraZeneca (NYSE:AZN) announced its quarterly earnings results on Friday, May, 18th. The company reported $0.48 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.28 by $0.20. The firm earned $5.18 billion during the quarter, compared to analysts' expectations of $5.24 billion. AstraZeneca had a net margin of 12.61% and a return on equity of 30.73%. AstraZeneca's revenue for the quarter was down 4.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.99 EPS. View AstraZeneca's Earnings History.

When is AstraZeneca's next earnings date?

AstraZeneca is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for AstraZeneca.

What guidance has AstraZeneca issued on next quarter's earnings?

AstraZeneca updated its FY18 earnings guidance on Friday, May, 18th. The company provided earnings per share (EPS) guidance of $3.30-3.50 for the period, compared to the Thomson Reuters consensus estimate of $3.46.

What price target have analysts set for AZN?

18 analysts have issued twelve-month price objectives for AstraZeneca's stock. Their predictions range from $35.00 to $42.00. On average, they anticipate AstraZeneca's stock price to reach $38.2833 in the next twelve months. View Analyst Ratings for AstraZeneca.

Are investors shorting AstraZeneca?

AstraZeneca saw a decrease in short interest in the month of April. As of April 30th, there was short interest totalling 8,995,025 shares, a decrease of 24.0% from the April 13th total of 11,832,140 shares. Based on an average daily volume of 3,760,290 shares, the short-interest ratio is currently 2.4 days.

Who are some of AstraZeneca's key competitors?

Some companies that are related to AstraZeneca include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), AbbVie (ABBV), Merck & Co. (MRK), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), GlaxoSmithKline (GSK), Bayer (BAYRY), Sanofi (SNY), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

Who are AstraZeneca's key executives?

AstraZeneca's management team includes the folowing people:

Mr. Pascal Soriot, Exec. Director & CEO (Age 59)
Mr. Marc Dunoyer, Exec. Director & CFO (Age 66)
Ms. Pam P. Cheng, Exec. Vice-Pres of Operations & Information Technology (Age 47)
Mr. Jefrey Pott, Gen. Counsel
Ms. Katarina Ageborg, Exec. VP of Sustainability & Chief Compliance Officer

Has AstraZeneca been receiving favorable news coverage?

Headlines about AZN stock have been trending somewhat positive this week, according to Accern. The research group identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AstraZeneca earned a news impact score of 0.08 on Accern's scale. They also assigned news coverage about the company an impact score of 46.45 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are AstraZeneca's major shareholders?

AstraZeneca's stock is owned by many different of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (0.50%), Epoch Investment Partners Inc. (0.34%), BlackRock Inc. (0.26%), Schafer Cullen Capital Management Inc. (0.18%), Federated Investors Inc. PA (0.17%) and Wells Fargo & Company MN (0.15%). View Institutional Ownership Trends for AstraZeneca.

Which institutional investors are selling AstraZeneca stock?

AZN stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Sei Investments Co., Wells Fargo & Company MN, Envestnet Asset Management Inc., Epoch Investment Partners Inc., Russell Investments Group Ltd., Farallon Capital Management LLC and Guggenheim Capital LLC. View Insider Buying and Selling for AstraZeneca.

Which institutional investors are buying AstraZeneca stock?

AZN stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Crawford Investment Counsel Inc., Senzar Asset Management LLC, Millennium Management LLC, Fisher Asset Management LLC, Global Financial Private Capital LLC, Thornburg Investment Management Inc. and PointState Capital LP. View Insider Buying and Selling for AstraZeneca.

How do I buy shares of AstraZeneca?

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately $37.04.

How big of a company is AstraZeneca?

AstraZeneca has a market capitalization of $93.82 billion and generates $22.47 billion in revenue each year. The company earns $3.00 billion in net income (profit) each year or $4.28 on an earnings per share basis. AstraZeneca employs 59,700 workers across the globe.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected]

MarketBeat Community Rating for AstraZeneca (AZN)

Community Ranking:		1.8 out of 5 ()
Outperform Votes:		521 (Vote Outperform)
Underperform Votes:		892 (Vote Underperform)
Total Votes:		1,413

MarketBeat's community ratings are surveys of what our community members think about AstraZeneca and other stocks. Vote "Outperform" if you believe AZN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AZN will underperform the S&P 500 over the long term. You may vote once every thirty days.

AstraZeneca (NYSE:AZN) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

18 Wall Street analysts have issued ratings and price targets for AstraZeneca in the last 12 months. Their average twelve-month price target is $38.2833, suggesting that the stock has a possible upside of 3.36%. The high price target for AZN is $42.00 and the low price target for AZN is $35.00. There are currently 1 sell rating, 5 hold ratings and 12 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.61	2.61	2.53	2.50
Ratings Breakdown:	1 Sell Rating(s) 5 Hold Rating(s) 12 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 5 Hold Rating(s) 12 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 7 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 8 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$38.2833	$38.1167	$36.2583	$34.7583
Price Target Upside:	3.36% upside	10.00% upside	7.98% upside	4.54% upside

AstraZeneca (NYSE:AZN) Consensus Price Target History

Price Target History for AstraZeneca (NYSE:AZN)

AstraZeneca (NYSE:AZN) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/25/2018	BMO Capital Markets	Reiterated Rating	Buy	$41.00	Low
3/19/2018	Jefferies Group	Upgrade	Hold ➝ Buy	$28.43 ➝ $36.70	Low
2/6/2018	Leerink Swann	Boost Price Target	Market Perform ➝ Market Perform	$36.00 ➝ $38.00	Medium
2/5/2018	Sanford C. Bernstein	Boost Price Target	Outperform	$40.00 ➝ $42.00	High
12/29/2017	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight		Low
10/18/2017	Citigroup	Upgrade	Buy		N/A
10/17/2017	Cowen	Reiterated Rating	Hold	$37.00	N/A
10/16/2017	Credit Suisse Group	Upgrade	Neutral ➝ Outperform		N/A
9/25/2017	BNP Paribas	Upgrade	Neutral ➝ Outperform		Medium
9/14/2017	Liberum Capital	Downgrade	Buy ➝ Hold		Low
9/6/2017	Natixis	Upgrade	Neutral ➝ Buy		Low
9/1/2017	Argus	Reiterated Rating	Buy	$35.00	Low
8/9/2017	Investec	Upgrade	Hold ➝ Buy		Low
8/9/2017	Piper Jaffray Companies	Reiterated Rating	Buy		Low
8/1/2017	Pareto Securities	Upgrade	Sell ➝ Hold		Low
7/28/2017	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight		High
7/13/2017	Goldman Sachs Group	Reiterated Rating	Sell		High
7/13/2017	Barclays	Reiterated Rating	Overweight		High
4/5/2017	UBS	Downgrade	Buy ➝ Neutral	$35.44 ➝ $25.55	N/A
2/21/2017	Berenberg Bank	Reiterated Rating	Buy		N/A
11/11/2016	Deutsche Bank	Reiterated Rating	Buy		N/A
11/11/2016	Beaufort Securities	Reiterated Rating	Hold		N/A
11/10/2016	Cantor Fitzgerald	Reiterated Rating	Buy		N/A
11/10/2016	Bank of America	Reiterated Rating	Buy	$41.37	N/A
11/10/2016	Shore Capital	Reiterated Rating	Hold		N/A

(Data available from 5/27/2016 forward)

AstraZeneca (NYSE:AZN) Earnings History and Estimates Chart

Earnings by Quarter for AstraZeneca (NYSE:AZN)

AstraZeneca (NYSE:AZN) Earnings Estimates

2018 EPS Consensus Estimate: $1.67

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	$0.42	$0.42	$0.42
Q2 2018	1	$0.40	$0.40	$0.40
Q3 2018	1	$0.39	$0.39	$0.39
Q4 2018	1	$0.46	$0.46	$0.46

AstraZeneca (NYSE AZN) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/26/2018
5/18/2018	3/31/2018	$0.28	$0.48	$5.2360 billion	$5.1780 billion	View	Listen
2/2/2018	Q4 2017	$0.44	$1.30	$5.4936 billion	$5.7770 billion	View	Listen
11/9/2017	Q3	$0.57	$1.12	$5.9999 billion	$6.2320 billion	View	N/A
7/27/2017	6/30/2017	$0.41	$0.87	$5.0391 billion	$5.0510 billion	View	N/A
4/27/2017	3/31/2017	$0.38	$0.99	$5.4045 billion	$5.4050 billion	View	N/A
2/2/2017	Q416	$0.51	$1.21	$5.43 billion	$5.5850 billion	View	Listen
11/10/2016	Q316	$0.48	$1.32	$5.95 billion	$5.6990 billion	View	N/A
7/28/2016	Q216	$0.76	$0.83	$5.56 billion	$5.60 billion	View	Listen
4/29/2016	Q1	$0.5970	$0.51	$5.96 billion	$6.12 billion	View	Listen
2/4/2016	Q415	$0.88	$0.94	$6.27 billion	$6.40 billion	View	N/A
11/5/2015	Q315	$0.51	$1.03	$5.90 billion	$5.85 billion	View	N/A
7/30/2015	Q2	$0.52	$1.21	$6.0159 billion	$5.8360 billion	View	Listen
4/24/2015	Q1	$1.07	$1.08	$5.8724 billion	$6.0570 billion	View	N/A
2/5/2015	Q314	$0.85	$0.76	$6.68 billion	$6.6830 billion	View	N/A
11/6/2014	Q3	$1.04	$1.05	$6.4398 billion	$6.5420 billion	View	N/A
7/31/2014	Q214	$1.09	$1.30	$6.24 billion	$6.4540 billion	View	N/A
4/29/2014	Q114	$1.23	$1.17	$6.32 billion	$6.42 billion	View	N/A
2/6/2014	Q413	$1.22	$1.23	$6.91 billion	$3.84 billion	View	N/A
10/31/2013	Q313	$1.27	$1.21	$6.45 billion	$6.25 billion	View	N/A
8/1/2013	Q213	$1.16	$1.20	$6.24 billion	$6.23 billion	View	N/A
4/25/2013		$1.36	$1.41	$6.5431 billion	$6.3850 billion	View	N/A
1/31/2013	Q412	$1.37	$1.56	$7.17 billion	$7.2820 billion	View	N/A
10/25/2012		$1.44	$1.51			View	N/A
7/26/2012		$1.38	$1.53			View	N/A
4/26/2012		$1.73	$1.81			View	N/A
2/2/2012		$1.57	$1.61			View	N/A
10/27/2011		$1.64	$1.71			View	N/A
7/28/2011		$1.74	$1.53			View	N/A
4/27/2011	Q1 2011	$1.02	$1.04			View	N/A
1/27/2011	Q4 2010	$0.67	$0.68			View	N/A
10/27/2010	Q3 2010	$0.76	$0.54			View	N/A
7/30/2010	Q2 2010	$0.80	$0.73			View	N/A
4/29/2010	Q1 2010	$0.86	$1.02			View	N/A
10/29/2009	Q3 2009	$0.68	$0.73			View	N/A
7/30/2009	Q2 2009	$0.68	$0.82			View	N/A
1/29/2009	Q4 2008	$0.59	$0.63			View	N/A
4/24/2008	Q1 2008	$0.60	$0.52			View	N/A
1/31/2008	Q4 2007	$0.50	$0.52			View	N/A

(Earnings results data provided by Zacks Investment Research)

AstraZeneca (NYSE:AZN) Dividend Information

AstraZeneca pays an annual dividend of $1.37 per share, with a dividend yield of 3.70%. AZN's most recent semiannual dividend payment was Monday, March 19. AstraZeneca pays out 32.01% of its earnings out as a dividend.

Most Recent Dividend:	3/19/2018
Annual Dividend:	$1.37
Dividend Yield:	3.70%
Dividend Growth:	-21.20% (3 Year Average)
Payout Ratio(s):	32.01% (Trailing 12 Months of Earnings) 80.59% (Based on This Year's Estimates) 71.73% (Based on Next Year's Estimates) 41.02% (Based on Cash Flow)

Dividend Payments by Quarter for AstraZeneca (NYSE:AZN)

AstraZeneca (NYSE:AZN) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/5/2018	semiannual	$0.95	5.62%	2/15/2018	2/16/2018	3/19/2018
7/28/2017	None	$0.44	2.98%	8/9/2017	8/11/2017	9/11/2017
2/3/2017	semiannual	$0.95	6.81%	2/15/2017	2/17/2017	3/20/2017
7/29/2016		$0.44		8/10/2016	8/12/2016	9/12/2016
2/5/2016		$0.93		2/17/2016	2/19/2016	3/21/2016
2/10/2015	semiannual	$1.90	5.57%	2/18/2015	2/20/2015	3/23/2015
8/1/2014	semiannual	$0.90	2.48%	8/13/2014	8/15/2014	9/15/2014
2/10/2014	special	$1.90	2.79%	2/19/2014	2/21/2014	3/24/2014
8/2/2013	semiannual	$0.90	3.52%	8/14/2013	8/16/2013	9/16/2013
2/1/2013	special	$1.90	3.72%	2/13/2013	2/15/2013	3/18/2013

(Data available from 1/1/2013 forward)

AstraZeneca (NYSE AZN) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 15.59%

Insider Trading History for AstraZeneca (NYSE:AZN)

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

AstraZeneca (NYSE AZN) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details

(Data available from 1/1/2013 forward)

AstraZeneca (NYSE AZN) News Headlines

Source:

Date	Headline
	Zacks: Analysts Anticipate AstraZeneca (AZN) to Announce $0.37 Earnings Per Share www.americanbankingnews.com - May 27 at 5:14 PM
	Luye Pharma Acquires AstraZeneca's Signature Products Seroquel and Seroquel XR www.prnewswire.com - May 27 at 9:52 AM
	AstraZeneca's (AZN) "Buy" Rating Reaffirmed at BMO Capital Markets www.americanbankingnews.com - May 25 at 3:11 PM
	Stocks to watch: Kingfisher, AstraZeneca, Imperial Brands, Roche www.ft.com - May 25 at 8:14 AM
	AstraZeneca cancer drug Imfinzi meets endpoint www.marketwatch.com - May 25 at 8:14 AM
	IMFINZI® (Durvalumab) Significantly Improves Overall Survival in the Phase III Pacific Trial for Unresectable Stage III Non-Small Cell Lung Cancer finance.yahoo.com - May 25 at 8:14 AM
	[$$] Stocks to watch: Kingfisher, AstraZeneca, Imperial Brands, Roche finance.yahoo.com - May 25 at 8:14 AM
	AstraZeneca (AZN) Receives Average Recommendation of "Hold" from Analysts www.americanbankingnews.com - May 24 at 5:42 PM
	Bicycle Therapeutics Expands Strategic Partnership with AstraZeneca www.businesswire.com - May 24 at 8:15 AM
	By Ron Leuty – Reporter, San Francisco Business Times www.bizjournals.com - May 24 at 8:15 AM
	AstraZeneca Heads to 2018 ASCO Annual Meeting with Its Diversified Oncology Portfolio and Next-Generation Pipeline finance.yahoo.com - May 24 at 8:15 AM
	AstraZeneca Reports Regulatory Submission In Japan For Forxiga - Quick Facts www.nasdaq.com - May 21 at 8:12 AM
	Form 6-K ASTRAZENECA PLC For: May 21 www.streetinsider.com - May 21 at 8:12 AM
	AstraZeneca potassium drug finally approved, threatening Vifor finance.yahoo.com - May 21 at 8:12 AM
	FDA's OKs AstraZeneca's Lokelma for hyperkalemia seekingalpha.com - May 21 at 7:11 AM
	AstraZeneca Stock Dips On Weak Q1 Profit; Backs FY18 View www.nasdaq.com - May 19 at 8:08 AM
	AstraZeneca Shareholder Approves All Resolutions www.nasdaq.com - May 19 at 8:08 AM
	AstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down www.msn.com - May 19 at 8:08 AM
	AstraZeneca insists future is bright after big Crestor sales hit finance.yahoo.com - May 19 at 8:08 AM
	AstraZeneca's (AZN) CEO Pascal Soriot on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - May 19 at 8:08 AM
	LOKELMATM Approved in the US for the Treatment of Adults with Hyperkalemia finance.yahoo.com - May 18 at 6:05 PM
	AstraZeneca plc Stock Slips on Q1 Earnings Miss, Falling Crestor Sales investorplace.com - May 18 at 12:24 PM
	AstraZeneca (AZN) Issues Quarterly Earnings Results www.americanbankingnews.com - May 18 at 9:32 AM
	AstraZeneca (AZN) Releases FY18 Earnings Guidance www.americanbankingnews.com - May 18 at 8:58 AM
	BRIEF-AstraZeneca CEO Says More Drug Industry Consolidation Possible www.reuters.com - May 18 at 8:29 AM
	BRIEF-Astrazeneca CEO Says In Ongoing Discussions With Investors On Bonuses www.reuters.com - May 18 at 8:29 AM
	AstraZeneca quarterly profit drops, sales rise www.marketwatch.com - May 18 at 8:29 AM
	AstraZeneca Q1 revenues down 4%; shares off 2% premarket seekingalpha.com - May 18 at 6:52 AM
	AstraZeneca hit by falling Crestor sales, higher costs www.cnbc.com - May 18 at 3:48 AM
	AstraZeneca (AZN) Said to Weigh Sale of US Rights to Crestor, Could Fetch Over $1 Billion - Bloomberg www.streetinsider.com - May 16 at 8:15 AM
	Emulate, Inc. and AstraZeneca Form Strategic Agreement to Work Side-by-Side on Organs-on-Chips Technology to ... www.businesswire.com - May 16 at 8:15 AM
	Short Interest in AstraZeneca (AZN) Decreases By 24.0% www.americanbankingnews.com - May 16 at 1:08 AM
	AstraZeneca (AZN) PT Raised to $41 at BMO Capital www.streetinsider.com - May 15 at 8:21 AM
	Free Stock Performance Review on Pfizer and Three More Drug Makers’ Stocks finance.yahoo.com - May 15 at 8:21 AM
	DPS Group gana un contrato en Suecia de AstraZeneca www.prnewswire.com - May 15 at 2:46 AM
	AstraZeneca Schweden vergibt Auftrag an DPS Group www.prnewswire.com - May 15 at 2:46 AM
	DPS Group vinner kontrakt med AstraZeneca i Sverige www.prnewswire.com - May 15 at 2:46 AM
	DPS Group remporte un contrat en Suède auprès d'AstraZeneca www.prnewswire.com - May 15 at 2:46 AM
	DPS Group Wins Contract in Sweden from AstraZeneca www.prnewswire.com - May 15 at 2:46 AM
	AstraZeneca Sees A Phase 3 Flop, But Not All Is Lost seekingalpha.com - May 14 at 8:21 AM
	Big Pharma Diversification Strategies Report 2018: Roche, Johnson & Johnson, and AstraZeneca - Active Acquirers in ... www.businesswire.com - May 11 at 8:19 AM
	AstraZeneca COPD drug fails phase 3 trial www.marketwatch.com - May 11 at 8:19 AM
	AstraZeneca's Fasenra Fails in Trial of Severe Lung Disease finance.yahoo.com - May 11 at 8:19 AM
	AstraZeneca (AZN) to Release Earnings on Friday www.americanbankingnews.com - May 11 at 1:02 AM
	What Analysts Recommend for Merck and Peers in May finance.yahoo.com - May 10 at 6:02 PM
	How Merck’s Human Vaccines Business Performed in 1Q18 finance.yahoo.com - May 9 at 8:15 AM
	AstraZeneca (AZN), Merck (MRK) LYNPARZA Tablets Receive EU Approval for Treatment of Platinum-Sensitive ... www.streetinsider.com - May 8 at 8:13 AM
	AstraZeneca sells rights for Seroquel to Luye Pharma for $538 million finance.yahoo.com - May 8 at 8:13 AM
	Procella Therapeutics and Smartwise Enter Collaboration With AstraZeneca to Develop Novel Cardiovascular and Catheter-based Therapies www.prnewswire.com - May 7 at 5:13 AM
	AstraZeneca (AZN) Downgraded by ValuEngine www.americanbankingnews.com - May 4 at 12:20 AM

AstraZeneca (NYSE:AZN) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

AstraZeneca (NYSE:AZN) Income Statement, Balance Sheet and Cash Flow Statement

AstraZeneca (NYSE AZN) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff